annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 22A Long-acting somatostatin analogues survival differences in limited- and
extensive-disease SCLC patients. (Abstract #7051)
K. Zarogoulidis, E. Eleftheriadou, G. Gerasimou, P. Zarogoulidis, I. Sapardanis,
T. Kontakiotis, G. Galaktidou, A. Gotzamani-Psarrakou, N. Karatzas
Brd. 22B Randomized phase II study (EORTC 08062) of amrubicin as single agent or in
combination with cisplatin versus etoposide-cisplatin as first-line treatment
in patients (pts) with extensive disease small cell lung cancer (ED SCLC).
(Abstract #7052)
M. O’Brien, J. Jassem, P. Lorigan, L. Bosquée, E. Marshall, F. Bustin, J. Stigt,
A. C. Dingemans, B. Hasan, J. P. Van Meerbeeck
Brd. 22C Retrospective study of irinotecan plus cisplatin induction followed by
concurrent thoracic irradiation with irinotecan plus cisplatin chemotherapy
for limited-disease small cell lung cancer. (Abstract #7053)
J. Jeong, J. Sung, H. Pyo, K. Cho, H. Kim, J. Han, T. Yun, G. Lee, J. Lee
Brd. 22D A phase II trial of combination chemotherapy with topotecan and amrubicin
in small cell lung cancer (SCLC). (Abstract #7054)
N. Nogami, K. Kiura, N. Takigawa, S. Harita, K. Chikamori, T. Shibayama,
M. Tabata, K. Hotta, T. Shinkai, M. Tanimoto
Brd. 22E Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line
treatment of small cell lung cancer (SCLC). (Abstract #7055)
D. M. Waterhouse, S. K. Morgan, D. R. Spigel, S. Shankar, B. Dharan,
D. E. Foose, K. Bhatt
Brd. 22F Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for
untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504
phase IB safety results. (Abstract #7056)
N. Ready, F. Dunphy, H. Pang, R. Heinze, J. Crawford, E. E. Vokes
Brd. 22G Phase II study of amrubicin and carboplatin in patients with the refractory or
relapsed small cell lung cancer (SCLC). (Abstract #7057)
T. Hirose, T. Shirai, S. Kusumoto, T. Sugiyama, T. Yamaoka, K. Okuda, T. Ohmori,
T. Ohnishi, M. Adachi A. Hermes
Brd. 23A Five-year follow-up of preoperative chemotherapy (Cx) of docetaxel with or
without cisplatin for clinical (c-) stage IB/II non-small cell lung cancer
(NSCLC): Report of a Japan Clinical Oncology Group study (JCOG0204).
(Abstract #7059)
H. Kunitoh, M. Tsuboi, H. Asamura, H. Tada, K. Nagai, T. Mitsudomi, T. Koike,
T. Shibata, N. Saijo, Japan Clinical Oncology Group
Brd. 23B Evaluation of neoadjuvant “window of opportunity” trials with targeted
therapy in patients with surgically resectable non-small cell lung cancer.
(Abstract #7060)
B. M. Stiles, F. Mirza, Y. Chiu, J. L. Port, P. C. Lee, S. Paul, N. K. Altorki
Brd. 23C Does induction chemoradiation effect perioperative mortality and overall
survival in patients undergoing pneumonectomy for non-small cell lung
cancer? (Abstract #7061)
J. Oxenberg, T. Li, B. Egleston, M. Goldberg, W. J. Scott
Brd. 23D Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as
induction regimen prior to surgery in chemotherapy-naive patients with
NSCLC stage IB-IIIA (INN06-study): Preliminary results. (Abstract #7062)
W. Hilbe, G. Pall, T. Schmid, B. Forstner, A. Zabernigg, H. Jamnig, A. Gaechter,
M. Freund, D. Kendler, E. Woell, Tyrolean Lung Cancer Study Group
Brd. 23E Docetaxel plus cisplatin versus vinorelbine plus cisplatin as adjuvant
chemotherapy in stage IB-IIIA non-small cell lung cancer: Preliminary result
of phase II pilot trial CHL001/TAX622. (Abstract #7063)
D. Chu, G. Wu, B. Han, X. Song, G. Chen, C. Zhou, Q. Wang, S. Wu, Y. Wang,
W. Zi-Ping
210